Our Impact on Drug Discovery and Development
Our research teams develop and apply cutting-edge approaches that speed therapeutic solutions for unmet health needs.
Moving More Treatments from the Lab to the Clinic
A researcher works in the lab at NCATS (Daniel Soñé Photography)
A new drug’s journey from the lab to the medicine cabinet can take up to 15 years. On the way, it passes through dozens of steps — and potential failure points. As a result, many never get approved for human use.
For more than 10 years, we’ve been making the drug discovery and development steps faster and more predictable. We built a pharmaceutical collection of nearly every drug approved for humans. We also built automated solutions to swiftly test drugs or combinations of them for new uses, including emerging infectious diseases. Through our partnerships with academia, industry and patient advocacy groups, we have enabled more than 45 promising new drugs to move into clinical trials.
Our newer drug discovery and development efforts focus on preparing for future pandemics and building a one-stop shop for finding, designing and testing new molecules with therapeutic potential.
Impact Stories
New Screening Tool Could Rapidly Reveal Better Cancer-Drug Combinations
Scientists at NCATS and NCI designed a screening method that could help predict in the lab how combos of three or more cancer drugs will work in people.
Tiny Antibodies May Provide New Tool to Fight COVID-19
An NIH-led team of scientists built a library of small antibodies and used it to find promising new therapeutic leads for halting viral activity.
Drug Discovery and Development Research Activities
We speed preclinical research on promising new medicines through a variety of research activities.
Assay Development and Screening Technology (ADST)
Our automation experts work closely with our lab scientists to support various research activities, including high-throughput screening, and assay development and optimization.
Matrix Combination Screening
Our experts use matrix combination screening technology to quickly identify promising drug combinations with the most potential to help patients.
Compound Management
Our compound management team uses sophisticated and automated techniques to supply chemicals for NCATS screening experiments to uncover new treatments for diseases.
Drug Discovery and Development Research News
New Path for a Gene Therapy Trial at NIH for a Rare Metabolic Disease
November 19, 2024 - NCATS News
- Bespoke Gene Therapy Consortium (BGTC)
- Our Impact on Clinical Trials
- Our Impact on Drug Discovery and Development
- Our Impact on Rare Diseases
- Platform Vector Gene Therapy (PaVe-GT)
Scientists at NCATS and other NIH institutes and centers are teaming up to advance a gene therapy treatment for MMA, a rare and potentially life-threatening genetic disorder.
Read ArticleAzome Therapeutics Enters Into CRADA With National Center for Advancing Translational Sciences to Investigate Novel Inflammasome Antagonist to Prevent Bronchopulmonary Dysplasia
November 13, 2024 - Grantee/Partner News
- Our Impact on Drug Discovery and Development
New Hope for Rapid-Acting Depression Treatment
October 24, 2024 - Grantee/Partner News
- Our Impact on Drug Discovery and Development
New Drug Screening Funnel Could Speed New Therapies for Gaucher Disease, Parkinson’s
October 11, 2024 - NCATS News
- Assay Development and Screening Technology (ADST)
- Our Impact on Drug Discovery and Development
- Our Impact on Rare Diseases
A three-step drug-testing process created by NIH scientists and their partners could find new therapies faster for Gaucher disease and Parkinson’s disease.